首页 / 产品 / 蛋白 / 活性蛋白

Recombinant Mouse Defb33 protein

  • 中文名: β-防御素33(Defb33)重组蛋白
  • 别    名: Defb33;Beta-defensin 33
货号: PA2000-3078
Price: ¥询价
数量:
大包装询价

产品详情

纯度>90%SDS-PAGE.
种属Mouse
靶点Defb33
Uniprot No Q30KN3
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间 21-62aa
氨基酸序列RKRNSKFRPCEKMGGICKSQKTHGCSILPAECKSRYKHCCRL
预测分子量 24.9 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于Defb33重组蛋白的模拟参考文献示例(注:Defb33相关研究较为有限,以下为假设性示例,建议通过学术数据库核实真实文献):

1. **《重组Defb33蛋白的制备及其抗菌活性研究》**

作者:李明等

摘要:本研究通过原核表达系统成功制备了重组Defb33蛋白,并验证其对多种革兰氏阳性菌的抑制效果,揭示了其在抗感染治疗中的潜在应用。

2. **《Defb33重组蛋白的结构与功能表征》**

作者:Smith J, et al.

摘要:利用X射线晶体学解析了Defb33重组蛋白的三维结构,结合体外实验证明其通过破坏微生物膜结构发挥抗菌作用,为优化防御素类药物提供依据。

3. **《Defb33在肠道黏膜免疫中的表达及重组蛋白应用》**

作者:陈华等

摘要:通过真核表达体系获得高纯度Defb33重组蛋白,动物实验表明其能增强肠道屏障功能,调节免疫反应,提示其在炎症性肠病治疗中的价值。

4. **《基因工程制备Defb33及其抗病毒活性探索》**

作者:Zhang Y, et al.

摘要:采用哺乳动物细胞表达系统生产重组Defb33.发现其对包膜病毒(如HSV-1)具有中和作用,机制可能与病毒膜蛋白相互作用有关。

**建议**:实际研究中Defb33的命名及功能可能存在差异,推荐使用PubMed、Web of Science等平台,以“DEFB33 recombinant”或“beta-defensin 33”为关键词检索最新文献,并注意核对基因命名准确性(如是否为DEFB103等相似基因)。

背景信息

**Background of Defb33 Recombinant Protein**

Defensin beta 33 (Defb33), a member of the β-defensin family, is a small cationic antimicrobial peptide (AMP) encoded by the DEFB33 gene in humans. β-defensins are evolutionarily conserved components of the innate immune system, primarily known for their broad-spectrum antimicrobial activity against bacteria, fungi, and viruses. They are expressed in epithelial and mucosal tissues, such as the skin, respiratory tract, and gastrointestinal system, serving as the first line of defense against pathogens.

Defb33 is characterized by its six conserved cysteine residues, forming three disulfide bonds that stabilize its structure and enhance its resistance to enzymatic degradation. Unlike some β-defensins with well-studied roles (e.g., DEFB1 or DEFB4), Defb33 remains less characterized, though emerging evidence suggests its involvement in microbial defense, wound healing, and immune modulation. Its expression is regulated by inflammatory cytokines, pathogen-associated molecular patterns (PAMPs), or tissue damage, linking it to both infection and chronic inflammatory conditions.

Recombinant Defb33 protein is produced using genetic engineering techniques, typically through heterologous expression in bacterial (e.g., *E. coli*) or mammalian cell systems. This allows large-scale production of the peptide for functional studies. Purification often involves chromatography methods to ensure proper folding and bioactivity. Research on recombinant Defb33 aims to elucidate its antimicrobial mechanisms, receptor interactions, and therapeutic potential, particularly in addressing antibiotic-resistant infections or immune dysregulation.

Overall, Defb33 represents a promising yet underexplored candidate in the development of novel antimicrobial agents and immunotherapies, highlighting the importance of further studies to unlock its clinical applications.

客户数据及评论

折叠内容

大包装询价

×